BioSpace News Archive

Sosei Group Corporation, announces its President & CEO, Chris Cargill, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in San Francisco, January 8-11, 2024.

RetinalGeniX Technologies Inc., announced that Anatoly Dritschilo, M.D. has joined the Company’s Medical Advisory Board.

Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223, an interleukin 2 mutant fusion protein (IL-2 mu-Fc) for the potential treatment of a broad spectrum of immunological diseases.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 with a presentation at 1:30 pm PT.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has entered into a grant agreement with The Michael J. Fox Foundation for Parkinson’s Research and has been awarded funding amounting to over USD 2 million.

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that the Company received alignment from FDA on key aspects of the Phase 3 clinical trial design to assess the safety and efficacy of OCU400 in patients with RHO and other gene mutations associated with Retinitis Pigmentosa (RP).

Nuvalent, Inc. (Nasdaq: NUVL) today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 7:30 a.m. PT in San Francisco.

Mallinckrodt plc, a global specialty pharmaceutical company, recently announced the publication of findings from a cost analysis of TERLIVAZ® for injection for adults with hepatorenal syndrome with rapid reduction in kidney function.

HOOKIPA Pharma Inc. announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share.